By Razak Musah Baba
LONDON--Canada has granted GlaxoSmithKline PLC's (GSK.LN)
Incruse Ellipta drug its first marketing authorization for the
treatment of lung diseases, the British pharmaceutical company said
Thursday.
Incruse Ellipta is a new once-daily treatment approved in Canada
for treatment of airflow obstruction with chronic obstructive
pulmonary disease, including chronic bronchitis and emphysema.
Following the decision, the company is now looking to progress
the regulatory submissions elsewhere, said Darrell Baker, SVP &
Head, Glaxo Global Respiratory Franchise.
Glaxo shares closed Thursday at GBP15.59, valuing the company at
GBP75.76 billion.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter:
@Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires